The effect of antihistamine cetirizine on ventricular repolarization in congenital long QT syndrome

Journal of Cardiovascular Electrophysiology

Volumn 18, Issue 7, 2007, Pages 691-695

  Hekkala, Anna Mari ^a   Swan, Heikki ^a   Väänänen, Heikki ^b   Viitasalo, Matti ^a   Toivonen, Lauri ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b AALTO UNIVERSITY   (Finland)

Author keywords

Body surface potential mapping; Cetirizine; Exercise test; Long QT syndrome; Transmural dispersion of repolarization; Ventricular repolarization

Indexed keywords

CETIRIZINE; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; ELECTROCARDIOGRAPHY; EPICARDIUM MAPPING; EXERCISE TEST; FEMALE; HEART RATE; HEART REPOLARIZATION; HUMAN; LONG QT SYNDROME; MALE; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; T WAVE;

ADULT; CETIRIZINE; FEMALE; HEART DEFECTS, CONGENITAL; HEART RATE; HEART VENTRICLES; HISTAMINE H1 ANTAGONISTS; HUMANS; LONG QT SYNDROME; MALE; MIDDLE AGED; SINGLE-BLIND METHOD;

EID: 34250672645     PISSN: 10453873     EISSN: 15408167     Source Type: Journal    
DOI: 10.1111/j.1540-8167.2007.00844.x     Document Type: Article

References (27)

1. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR: Torsades de pointes occurring in association with terfenadine use. JAMA 1990 264: 2788 2790.
2. Woosley RL, Chen Y, Freiman JP, Gillis RA: Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993 269: 1532 1536.
3. Roy ML, Dumaine R, Brown A: HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation 1996 94: 817 822.
4. Taglialatela M, Castaldo P, Pannaccione A, Giorgio G, Annunziato L: Human ether-a-gogo related gene (HERG) K+ channels as pharmacological targets. Biochem Pharmacol 1998 55: 1741 1746.
5. Taglialatela M, Castaldo P, Pannaccione A, Giorgio G, Genovese A, Marone G, Annunziato L: Cardiac ion channels and antihistamines: Possible mechanisms of cardiotoxicity. Clin Exp Allergy 1999 29: 182 189.
6. Gottlieb S: Antihistamine drug withdrawn by manufacturer. News. BMJ 1999 319: 7.
7. Camm AJ, Janse MJ, Roden DM, Rosen MR, Cinca J, Cobbe SM: Congenital and acquired long QT syndrome. Eur Heart J 2000 21: 1232 1237.
8. Taglialatela M, Pannaccione A, Castaldo P, Giorgio G, Zhou Z, January CT, Genovese A, Marone G, Annunziato L: Molecular basis for the lack of HERG K+ channel block-related cardiotoxicity by the H1 receptor blocker cetirizine compared with other second-generation antihistamines. Mol Pharmacol 1998 54: 113 121.
9. Carmeliet E: Effects of cetirizine on the delayed K+ currents in cardiac cells: Comparison with terfenadine. Br J Pharmacol 1998 124: 663 668.
10. Weissenburger J, Noyer M, Cheymol G, Jaillon P: Electrophysiological effects of cetirizine, astemizole and D-sotalol in a canine model of long QT syndrome. Clin Exp Allergy 1999 29: 190 196.
11. de Abajo FJ, Garcia Rodriquez LA: Risk of ventricular arrhythmias associated with nonsedating antihistamine drugs. J Clin Pharmacol 1999 47: 307 313.
12. Piippo K, Swan H, Pasternack M, Chapman H, Paavonen K, Viitasalo M, Toivonen L, Kontula K: A founder mutation of the potassium channel KCNQ1 in long QT syndrome: Implications for estimation of disease prevalence and molecular diagnostics. J Am Coll Cardiol 2001 37: 562 568.
13. Fodstad H, Swan H, Laitinen P, Piippo K, Paavonen K, Viitasalo M, Toivonen L, Kontula K: Four potassium channel mutations account for 73% of the genetic spectrum underlying long QT syndrome (LQTS) and provide evidence for a strong founder effect in Finland. Ann Med 2004 36: 53 63.
14. Oikarinen L, Paavola M, Montonen J, Viitasalo M, Mäkijärvi M, Toivonen L, Katila T: Magnetocardiographic QT interval dispersion in postmyocardial infarction patients with sustained ventricular tachycardia: Validation of automated QT measurements. PACE 1998 21: 1934 1942.
15. Lepechkin E, Surawicz B: The measurement of the Q-T-interval of the electrocardiogram. Circulation 1952 6: 378 387.
16. Bazett HC: An analysis of the time-relations of electrocardiograms. Heart 1920 7: 353 370.
17. Simons FER, Simons KJ: Clinical pharmacology of new histamine H1 receptor antagonists. Clin Pharmacokinet 1999 36: 329 349.
18. Sale ME, Barbey JT, Woosley RL, Edwards D, Yeh J, Thakker K, Chung M: The electrocardiographic effects of cetirizine in normal subjects. Clin Pharmacol Ther 1994 54: 295 301.
19. Roden DM: Long QT syndrome: Reduced repolarization reserve and the genetic link. J Int Med 2006 259: 59 69.
20. Viitasalo M, Oikarinen L, Swan H, Väänänen H, Glatter K, Laitinen PJ, Kontula K, Barron HV, Toivonen L, Scheinman MM: Ambulatory electrocardiographic evidence of transmural dispersion of repolarization in patients with long QT-syndrome type 1 and 2. Circulation 2002 106: 2473 2487.
21. Viitasalo M, Karjalainen J: QT intervals at heart rates from 50 to 120 beats per minute during 24-hour electrocardiographic recordings in 100 healthy men. Effects of atenolol. Circulation 1992 86: 1439 1442.
22. Takenaka K, Tomohiko A, Shimizu W, Kobori A, Nimomiya T, Otani H, Kubota T, Takaki H, Kamakura S, Horie M: Exercise stress test amplifies genotype-phenotype correlation in the LQT1 and LQT2 forms of the long-QT syndrome. Circulation 2003 107: 838-844.
23. Hekkala AM, Väänänen H, Swan H, Oikarinen L, Viitasalo M, Toivonen L: Reproducibility of computerized measurements of QT-interval from multiple leads at rest and during recovery. ANE 2006 11: 318 326.
24. Yan G-X, Antzelevitch C: Cellular basis for the normal T wave and the electrocardiographic manifestations of the long QT syndrome. Circulation 1998 98: 1928 1936.
25. Belardinelli L, Antzelevitch C, Vos M: Assessing predictors of drug-induced torsades de pointes. Trends Pharmacol Sciences 2003 24: 619 625.
26. Antzelevitch C: Arrhythmogenic mechanisms of QT prolonging drugs: Is QT prolongation really the problem? J Electrocardiol 2004 37: 15 24.
27. Haverkamp W, Breithardt G, Camm AJ, Janse MJ, Rosen MR, Antzelevitch C, Escande M, Franz M, Malik M, Moss A, Shah R: The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: Clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Eur Heart J 2000 21: 1216 1231.